Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical tr…
Biotechnology
US, Gaithersburg [HQ]
Ratios
5 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross Margin | - - | - - | - - | - - | 98.15 | |
| Profit Margin | - - | - - | - - | - - | -64.08 | |
| Operating Margin | - - | - - | - - | - - | -81.47 | |
|
EPS Growth
|
- - | -84.62 | -86.46 | -135.75 | 65.17 | |
| EPS USD | -52.00 | -96.00 | -179.00 | -422.00 | -147.00 | |
| Return on Assets (ROA) | -41.23 | -55.63 | -49.64 | -59.30 | -8.57 | |
| Return on Equity (ROE) | 54.90 | 50.37 | 52.61 | -90.80 | -14.56 | |
| Return on Invested Capital (ROIC) | 54.90 | 50.37 | 52.69 | -64.36 | -15.56 | |
| Solvency | ||||||
| Equity Ratio | - - | -100 | - - | - - | - - | |
| Debt/Assets | - - | - - | 0.08 | 28.08 | 11.83 | |
| Debt/Equity | - - | - - | -0.08 | 43.00 | 20.11 | |
| Debt/EBITDA | 195.93 | 148.08 | 160.75 | -12.81 | 338.07 | |
|
Debt/Capitalization
|
- - | - - | -0.08 | 30.07 | 16.75 | |
| Long-Term Debt/Capitalization | - - | - - | - - | 20.29 | 9.48 | |
| Interest Debt per Share USD | - - | - - | - - | 2.04 | 2.11 | |
| Debt Growth | - - | - - | - - | 88,031.00 | 10.77 | |
| Liquidity | ||||||
| Current Ratio | 1,252.68 | 936.39 | 759.91 | 470.72 | 605.87 | |
| Quick Ratio | 1,137.81 | 884.01 | 1,201.76 | 449.50 | 593.73 | |
| Cash Ratio | 1,137.81 | 884.01 | 704.73 | 113.20 | 333.72 | |
| Operating Cash Flow Ratio | -600 | -500 | -300 | -100 | 100 | |
| Turnover | ||||||
| Inventory Turnover | - - | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | - - | - - | |
| Payables Turnover | 18.67 | 124.80 | 78.09 | 24.57 | 77.89 | |
|
Asset Turnover
|
- - | - - | - - | - - | 13.37 | |
| Fixed Turnover | - - | - - | - - | - - | 157.99 | |
| Coverage | ||||||
| Interest Coverage | - - | - - | -650,180.00 | -11,119.71 | -2,339.41 | |
| Asset Coverage | - - | - - | 114,000 | 300 | 700 | |
| Cash Flow Coverage (CFGR) | - - | - - | -54,238.00 | -112.68 | 212.62 | |
| EBITDA Coverage | - - | - - | -650,100 | -10,800 | -2,200 | |
| Dividend Coverage | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||
| Dividend Yield | - - | - - | - - | - - | - - | |
| Earnings Yield | -3.08 | -5.70 | -10.65 | -13.62 | -2.65 | |
|
Price/Earnings (P/E)
|
-3,251.29 | -1,755.82 | -939.14 | -734.23 | -3,773.39 | |
| Price/Earnings Growth (PEG) | - - | -20.75 | -10.86 | -5.41 | 57.90 | |
|
Price/Book (P/B)
|
-1,784.84 | -884.39 | -494.07 | 666.69 | 549.55 | |
| Price/Tangible Book (P/TB) | -1,784.84 | -884.39 | -494.07 | 666.69 | 549.55 | |
| Price/Sales (P/S) | - - | - - | - - | - - | 2,417.91 | |
|
Price/Cash Flow (P/CF)
|
-3,112.73 | -1,966.13 | -1,106.93 | -1,375.99 | 1,285.05 | |
| Price/Free CF (P/FCF) | -2,585.04 | -1,907.04 | -1,000.27 | -1,345.15 | 1,432.97 | |
| Price/Operating CF (P/OCF) | -3,112.73 | -1,966.13 | -1,106.93 | -1,375.99 | 1,285.05 |